Bayer, Onyx submit cancer drug Nexavar for U.S., EU approval

07/3/2013 | Pharmaceutical Business Review Online

Bayer HealthCare and Onyx Pharmaceuticals have filed regulatory applications with the FDA and the European Medicines Agency for approval to market Nexavar, or sorafenib, as a treatment for locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer. The applications were based on data from a late-stage trial showing that the drug significantly improved progression-free survival compared with a placebo.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY